Alaunos Therapeutics, Inc. announced a new preclinical statistical analysis of its metabolic candidate ALN1003 from a non-GLP diet-induced obesity mouse study. The analysis, using standard ANCOVA and HC3 standard errors, showed that ALN1003-treated animals had lower liver weight adjusted for body fat percentage compared to controls. Alaunos Therapeutics, Inc. is a biotechnology company developing investigational oral, non-hormonal, non-incretin small-molecule metabolic candidates.